Drug Profile
Research programme: purine modulators - Rocket
Alternative Names: INO-1271Latest Information Update: 09 Jan 2018
Price :
$50
*
At a glance
- Originator Inotek Pharmaceuticals
- Class
- Mechanism of Action Purinergic receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 04 Jan 2018 Rocket Pharmaceuticals merged with Inotek Pharmaceuticals and the combined company was named Rocket Pharmaceuticals
- 08 Oct 2007 Discontinued - Preclinical for Glaucoma in USA (unspecified route)
- 23 Jul 2007 Preclinical trials in Glaucoma in USA (unspecified route)